ArticleOncology letters2025
Prognostic value of M2 macrophage-related genes and their importance in the immunotherapy response in hepatocellular carcinoma.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- KLRB1 gene in tumor immune regulation and disease prognosis: a multidimensional role review.Discover oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver hepatocellular carcinoma (LIHC) is a major contributor to cancer-associated mortality worldwide, with a poor prognosis due to late-stage diagnosis and limited therapeutic options. M2 macrophages serve crucial roles in the tumor microenvironment (TME), contributing to tumor progression, immune evasion and resistance to therapy. However, the prognostic importance of M2 macrophage-related genes in LIHC and their potential for predicting responses to immunotherapy remain underexplored. A bioinformatics analysis was performed using The Cancer Genome Atlas data to identify M2 macrophage-related genes in LIHC. Differential expression and weighted gene co-expression network analysis were used to identify key gene modules and a prognostic model was developed and validated using Kaplan-Meier analysis and receiver operating characteristic curves. The immune therapy response was assessed using tracking of indels by decomposition and Submap analyses. Killer cell lectin like receptor B1 (KLRB1) was knocked down in HuH-7 cells and overexpressed in HuH-1 cells to evaluate its effect on tumor cells and macrophage regulation. The effect on human umbilical vein endothelial cell tube formation was also assessed. A total of two M2 macrophage-related genes (KLRB1 and phosphatidylinositol-5-phosphate 4-kinase type 2α) were identified as notable prognostic biomarkers for LIHC. The prognostic model demonstrated certain predictive power, with high-risk patients exhibiting markedly worse overall survival. This model was validated in external datasets and associated with immune infiltration patterns. Furthermore, low-risk patients were more likely to respond to immune checkpoint blockade therapy. The inhibition of KLRB1 enhanced LIHC cell activity and increased macrophage polarization from the M0 phenotype to the M2 phenotype by regulating LIHC cell secretions. In conclusion, M2 macrophage-related genes are valuable prognostic biomarkers in LIHC. The prognostic model effectively stratifies patients by survival risk and predicts immunotherapy responses, thereby highlighting the potential for improved TME-targeted therapies in LIHC. The mechanism of KLRB1 regulation in LIHC-macrophage interactions and its impact on LIHC activities were also evaluated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.